Aptorum Group to Hold Investor Webinar and Q&A Session with President on May 19
2020年5月18日 - 9:00PM
ビジネスワイヤ(英語)
Aptorum Group Limited (NASDAQ:APM), a biopharmaceutical company
focused on the development of novel therapeutics to address global
unmet medical needs, today announced President and Executive
Director Darren Lui will share insight into the company’s recent
developments and upcoming milestones during an investor webinar on
Tuesday, May 19, 2020 at 4:00 p.m. ET. A live Q&A session with
Lui will follow the presentation.
To participate in the webinar, please register at
https://www.redchip.com/corporate/webinar_register/59
Questions can be pre-submitted to craig@redchip.com or online
during the event.
About Aptorum Group
Aptorum Group Limited (Nasdaq:APM) is a pharmaceutical company
dedicated to developing and commercializing novel therapeutics to
tackle unmet medical needs. Aptorum Group’s current drug pipeline
includes indications in orphan diseases, infectious diseases and
metabolic diseases, a number of which are targeted to enter
clinical trial phases in H2 2020. Aptorum Group is also launching a
women’s health supplement, Dioscorea Opposita Bioactive
Nutraceutical Tablets, which will be commercialized soon.
For more information about the Company, please visit
www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release includes statements concerning Aptorum Group
Limited and its future expectations, plans and prospects that
constitute "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. For this purpose,
any statements contained herein that are not statements of
historical fact may be deemed to be forward-looking statements. In
some cases, you can identify forward-looking statements by terms
such as "may," "should," "expects," "plans," "anticipates,"
"could," "intends," "target," "projects," "contemplates,"
"believes," "estimates," "predicts," "potential," or "continue," or
the negative of these terms or other similar expressions. Aptorum
Group has based these forward-looking statements, which include
statements regarding projected timelines for application
submissions and trials, largely on its current expectations and
projections about future events and trends that it believes may
affect its business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this
press release and are subject to a number of risks, uncertainties
and assumptions including, without limitation, risks related to its
announced management and organizational changes, the continued
service and availability of key personnel, its ability to expand
its product assortments by offering additional products for
additional consumer segments, development results, the company’s
anticipated growth strategies, anticipated trends and challenges in
its business, and its expectations regarding, and the stability of,
its supply chain, and the risks more fully described in Aptorum
Group’s Form 20-F and other filings that Aptorum Group may make
with the SEC in the future. As a result, the projections included
in such forward-looking statements are subject to change and could
be materially different from those described herein. Aptorum Group
assumes no obligation to update any forward-looking statements
contained in this press release as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200518005247/en/
Investor Relations: Tel: +852 2117 6611 Email:
investor.relations@aptorumgroup.com
Craig Brelsford RedChip Companies Tel: (407) 571.0902 Email:
craig@redchip.com
Media: Tel: + 852 2117 6611 Email: info@aptorumgroup.com
Aptorum (NASDAQ:APM)
過去 株価チャート
から 3 2024 まで 4 2024
Aptorum (NASDAQ:APM)
過去 株価チャート
から 4 2023 まで 4 2024